Back to Search
STEPHEN CANNISTRA, M.D.
M.D.
Medical Oncology Physician
NPI: 1174552780Individual
Specialties, Licenses & Credentials
Research & Publications (20)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
PMID 18024865·J Clin Oncol·2007
3-trial
Progress in the management of gynecologic cancer: consensus summary statement.
PMID 12743127·J Clin Oncol·2003
8-other
Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer.
PMID 19038057·BMC Med Genomics·2008
8-other
Challenges and pitfalls of combining targeted agents in phase I studies.
PMID 18669449·J Clin Oncol·2008
8-other
Gene-expression profiling in epithelial ovarian cancer.
PMID 18648354·Nat Clin Pract Oncol·2008
6-review
BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease.
PMID 18094398·Clin Cancer Res·2007
8-other
IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer.
PMID 17914107·Endocr Relat Cancer·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 330 BROOKLINE AVE, BETH ISRAEL DEACONESS MEDICAL CENTER
BOSTON, MA 02215 - Phone
- (617) 667-4283
Quick Facts
- NPI
- 1174552780
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile